In a recent post at In the Pipeline, Derek Lowe answers a reader’s question about how best to promote drug […]

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Festo: The plague continues
Go to paperABSTRACT: This paper reviews the law on the doctrine of equivalence and prosecution history estoppel and explores ho…

This is a guest post by Steve Sapletal,  a director in West Monroe Partners‘ M&A practice. Do you have a response to

I have created a six-hour biotechnology education series at bit.ly/LfbSdS, and I want to highlight the policy discussion here. It is

I have created a six-hour biotechnology education series at bit.ly/LfbSdS, and I want to highlight the policy discussion here. It is

I have created a six-hour biotechnology education series at bit.ly/LfbSdS, and I want to highlight the policy discussion here. It is

On a recent press tour of New Jersey I was introduced to PTC Therapeutics, a fascinating company that is developing

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Seeds, food and trade wars: Public opinion and policy responses in the USA and Europe
Go to paperABSTRACT: The political debate over genetically modified fo…

In the wake of the repositioning of Maryland’s Shady Grove Incubator from biotechnology to cyber security, Virginia has stepped up

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post?